Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Recurrent Respiratory Papillomatosis
Interventions
DRUG

celebrex (celecoxib)

Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight \>25 kg

DRUG

placebo

similar appearing capsules containing inert ingredients

Trial Locations (7)

11040

Long Island Jewish Medical Center, New Hyde Park

23507

Eastern Virginia Medical School, Norfolk

35294

University of Alabama Birmingham, Birmingham

37232

Vanderbilt University, Nashville

52242

University of Iowa, Iowa City

57104

Sanford Health /USD, Sioux Falls

94115

UCSF Medical Center, San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIH

collaborator

University of Iowa

OTHER

collaborator

Eastern Virginia Medical School

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

Vanderbilt University

OTHER

collaborator

Sanford Health

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

lead

Northwell Health

OTHER